National Measurement Institute




CERTIFIED REFERENCE MATERIAL CERTIFICATE OF ANALYSIS

NMIA S027: Drostanolone enanthate

Report ID: S027.2020.03 (Bottled 230202)

Chemical Formula: C₂₇H₄₄O₃ Molecular Weight: 416.6 g/mol



Certified value

Batch No.	CAS No.	Purity (mass fraction)
14-S-04	13425-31-5	97.9 ± 1.5%

The uncertainty has been calculated according to ISO Guide 35 and is stated at the 95% confidence limit (k = 2).

IUPAC name: $(2\alpha,5\alpha,8\xi,9\xi,14\xi,17\beta)$ -2-Methyl-3-oxoandrostan-17-yl heptanoate.

Expiration of certification: The property values are valid till 26 March 2025, i.e. five years from the date of re-certification provided the **unopened** material is handled and stored in accordance with the recommendations below. The material as issued in the unopened container and stored as recommended below should be suitable for use beyond this date, subject to confirmation of batch stability from the issuing body. The expiry date/shelf life does not apply to sample bottles that have been opened. In such cases it is recommended that the end-user conduct their own in-house stability trials.

Description: White powder prepared by synthesis, and certified for identity and purity by NMIA. Packaged in amber glass bottles with a septum and crimped aluminium cap or screw top cap.

Intended use: This certified reference material is suitable for use as a primary calibrator.


Instructions for use: Equilibrate the bottled material to room temperature before opening.

Recommended storage: When not in use this material should be stored at or below 4 °C in a closed container in a dry, dark area.

Metrological traceability: The certified purity value is traceable to the SI unit for mass (kg) through Australian national standards via balance calibration. In the mass balance approach all impurities are quantified as a mass fraction and subtracted from 100%. **Stability:** This material has demonstrated stability over a minimum period of five years. The measurement uncertainty at the 95% confidence interval includes a stability component which has been estimated from annual stability trials. The long-term stability of the compound in solution has not been examined.

Homogeneity assessment: The homogeneity of the material was assessed using purity assay by GC-FID on ten randomly selected 1-2 mg sub samples of the material. The material was judged to be sufficiently homogeneous at this level of sampling as the variation in analysis results between samples was not significantly different at a 95% confidence level from that observed on repeat analysis of the same sample.

Safety: Treat as a hazardous substance. Use appropriate work practices when handling to avoid skin or eye contact, ingestion or inhalation of dust. Refer to the provided safety data sheet.



Dr Stephen R. Davies, Team Leader, Chemical Reference Materials, NMI. 8 February 2023

NATA Accreditation No. 198 / Corporate Site No. 14214.

Legal notice: Terms and Conditions associated with the provision of this reference material can be found on the NMIA website.

Characterisation Report:

The identity was confirmed by a range of spectroscopic techniques, NMR, IR and MS. The certified purity value was obtained by mass balance from a combination of traditional analytical techniques, including GC-FID, thermogravimetric analysis, Karl Fischer analysis and ¹H NMR spectroscopy. The purity value is calculated as per Equation 1.

Purity = $(100 \% - I_{ORG}) \times (100 \% - I_{VOL} - I_{NVR})$

Equation 1

I_{ORG} = Organic impurities of related structure, I_{VOL} = volatile impurities, I_{NVR} = non-volatile residue.

Supporting evidence is provided by qualitative headspace GC-MS analysis of occluded solvents and elemental microanalysis.

Warning:

This material has shown signs of decomposition when injected at elevated temperature (250 °C) onto a GC column, affording an artifact impurity peak immediately tailing the main analyte. This effect has been observed in drostanolone and other drostanolone esters, and has tentatively been attributed to isomerization at C2.

GC-FID:

Instrument: Agilent 7890 or Agilent 6890

Column: HP-1MS, 30 m \times 0.32 mm I.D. \times 0.25 μ m or HP-5, 30 m \times 0.32 mm I.D. \times 0.25 μ m

Program: 250 °C (1 min), 10 °C/min to 300 °C (10 min)

Injector: 250 °C

Detector Temp: 320 °C

Carrier: Helium

Split ratio: 20/1

Relative mass fraction of the main component including the GC artifact:

Initial analysis: Mean = 98.9%, s = 0.04% (10 sub samples in duplicate, April 2014) Re-analysis: Mean = 98.9%, s = 0.04% (5 sub samples in duplicate, April 2015) Re-analysis: Mean = 98.9%, s = 0.04% (5 sub samples in duplicate, March 2016) Re-analysis: Mean = 98.8%, s = 0.04% (5 sub samples in duplicate, March 2017) Re-analysis: Mean = 98.8%, s = 0.06% (5 sub samples in duplicate, March 2020)

HPLC:

Instrument: Waters Model 1525 Binary pump, 717 plus autosampler

Column: Alltima C-18, 5 μm (4.6 mm x 150 mm)

Column oven: 40 °C

Mobile Phase: Acetonitrile/MilliQ water (95:5 v/v)

Flow rate: 1.0 mL/min
Detector: Waters ELSD 2424
Relative peak area of the main component:

Initial analysis: Mean = 99.7%, s = 0.08% (10 sub samples in duplicate, March 2014)

Karl Fischer analysis:

Moisture content 0.1% mass fraction (March 2014) Moisture content 0.1% mass fraction (April 2015) Moisture content 0.2% mass fraction (March 2016) Moisture content 0.1% mass fraction (March 2017) Moisture content 0.1% mass fraction (January 2020)

Thermogravimetric analysis:

Volatile content 1% and non-volatile residue < 0.2% mass fraction (April 2014)

Spectroscopic and other characterisation data

GC-MS: Instrument: Agilent 6890/5973

Column: TG-1MS, 30 m x 0.25 mm l.D. x 0.25 μ m Program: 180 °C (1 min), 10 °C/min to 300 °C (10 min)

 $\begin{array}{ll} \mbox{Injector:} & 250 \ \mbox{°C} \\ \mbox{Split ratio:} & 20/1 \\ \mbox{Transfer line temp:} & 280 \ \mbox{°C} \end{array}$

Carrier: Helium, 1mL/min Scan range: 50-550 *m/z*

The retention time of the parent compound is reported with the major peaks in the mass spectra. The latter are

reported as mass/charge ratios and (in brackets) as a percentage relative to the base peak.

Parent (16.0 min): 416 (M+, 1), 286 (100), 271 (73), 258 (13), 201 (11), 161 (19), 149 (58), 138 (33),

113 (75), 94 (46), 81 (24), 55 (28) m/z

HS-GC-MS: Instrument: Agilent 6890/5973/G1888

Column: DB-624, 30 m x 0.25 mm l.D. x 1.4 μm

Program: 50 °C (5 min), 7 °C/min to 120 °C, 15 °C/min to 220 °C (8.3 min)

Injector: 150 $^{\circ}$ C Transfer line temp: 280 $^{\circ}$ C

Carrier: Helium, 1.2 mL/min

Split ratio: 50/1

Solvents detected: Ethyl acetate, hexane, heptanoic acid

TLC: Conditions: Kieselgel 60F₂₅₄. Hexane/ethyl acetate (7:3)

Single spot observed, $R_f = 0.9$. Visualisation with vanillin

IR: Biorad FTS3000MX FT-IR

Range: 4000-400 cm⁻¹, KBr powder

Peaks: 2932, 2870, 2857, 1733, 1710, 1447, 1375, 1300, 1234, 1177, 1104, 1034, 993, 948,

911, 754, 725, 614 cm⁻¹

¹H NMR: Instrument: Bruker Avance-400

Field strength: 400 MHz

Solvent: CDCl₃ (7.26 ppm)

Spectral data: δ 0.73 (1H, m), 0.80 (3H, s), 0.88 (3H, t, J = 6.8 Hz), 0.86-0.94 (1H, m), 1.00 (3H, d, J =

6.5 Hz), 1.02-1.10 (5H, m), 1.16 (1H, dt, J = 4.1, 13.0 Hz), 1.25-1.39 (10H, m), 1.39-1.54 (3H, m), 1.56-1.65 (4H, m), 1.71 (2H, m), 2.04 (1H, dd, J = 6.2, 13.4 Hz), 2.08 (1H, dd, J = 3.7, 14.4 Hz), 2.15 (1H, m), 2.27-2.31 (3H, m), 2.45 (1H, septet, J = 6.3 Hz), 4.59

(1H, dd, J = 8.0, 9.0 Hz) ppm

¹³C NMR: Instrument: Bruker Avance-400

Field strength: 101 MHz

Solvent: CDCl₃ (77.2 ppm)

Spectral data: δ 12.4, 12.6, 14.2, 14.8, 21.1, 22.7, 23.7, 25.2, 27.7, 28.7, 29.0, 31.4, 31.6, 34.8, 35.2,

36.7, 37.0, 41.3, 42.9, 44.9, 48.1, 48.7, 50.7, 54.0, 82.6, 174.1, 213.2 ppm

Melting point: 63-64 °C

Microanalysis: Found: C = 77.7%; H = 10.8% (April, 2014)

Calculated: C = 77.8%; H = 10.6% (Calculated for $C_{27}H_{44}O_3$)